Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
The primary objective is to determine whether the addition of bevacizumab to a regimen of
carboplatin plus paclitaxel significantly improves Progression Free Survival (PFS) for
patient with Stage III suboptimally cytoreduced or Stage IV ovarian, primary peritoneal or
fallopian tube carcinomas.